Dr. Hans-Peter Gerber brings 30 years of R&D experience in oncology drug development, specializing in antibody-drug conjugates (ADCs), redirected T-cell targeting bispecifics and adoptive T-cell therapies. Notably, he has contributed to the development of 6 of the 15 approved ADCs. In September 2023, Hans-Peter joined Sutro Biopharma as CSO, leading a research team of 80 FTEs. He co-founded Codeable Therapeutics in 2022, serves as Chairman of the Board at T-CURX, a CAR-T start-up, and is a board member at Athebio. From 2018 to 2022, he was CSO and SVP at 3T Biosciences, raising over $50M as interim CEO. He was an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim for $1.5B in 2021. Previously, Hans-Peter built the R&D organization at Maverick Therapeutics, acquired by Takeda for $525M in 2021. Between 1995 and 2017, Hans-Peter held increasing responsibilities at Genentech, Seattle Genetics, and Pfizer. His work led to over 10 IND filings and 3 BLAs, including Avastin and 2 ADCs (Mylotarg, Besponsa). An internationally recognized leader in oncology R&D, Hans-Peter has authored over 100 peer-reviewed papers and holds over 100 patents. He received his MS in Biochemistry and PhD in Molecular Biology from the University of Zurich, Switzerland.